Amgen Drugs May Boost Survival After a Nuclear Attack, FDA Says

Amgen Drugs May Boost Survival After a Nuclear Attack, FDA Says

Amgen via Bloomberg

Neulasta, Amgen’s second best-selling drug, and Neupogen together generated about $5.4 billion in sales last year for the Thousand Oaks, California-based company, according to data compiled by Bloomberg.